Pharmaceutical Companies in Europe

At Julius Clinical, science is the foundation. Combined with flexibility, creativity, and innovation, our scientific approach enables fast, efficient, and high quality execution of complex clinical development programs. Our skilled and loyal networks of investigators all around the world allow us to offer superior recruitment in therapeutic area’s such as cardiology, diabetes, CNS and infectious diseases. Our partners include leading pharmaceutical, biotech, medical device, and food companies, as well as academic investigators. We focus on clinical trials that are likely to have a major impact on medicine and on people’s lives. This type of demanding research requires more than a ‘one-size-fits-all’ approach, and our fusion of scientific and operational expertise enables to deliver results efficiently, on time and budget. Julius Clinical has on its staff internationally recognised academic leaders who are actively involved in the design, conduct, and interpretation of clinical trials. This scientific expertise and credibility, combined with personal links with peers around the world, means that the company has a truly global reach and reputation. Through our global networks we can quickly select the most appropriate and high-performing sites to take part in a trial, and ensure that investigators are inspired and motivated.

RAFARM We evolve beyond the obvious; we make a positive impact on people’s lives and ensure a healthier future. How far can we get? Well, we take a step forward, daily. Every day we discover new paths Every day we go beyond the obvious, we march ahead towards a healthier future. We are RAFARM, innovation-driven, dynamically growing, and one of the largest Greek pharmaceutical companies with an outward-looking orientation. We invest 10% of net turnover in Research and Development >100 RAFARM development products 10 new products are being developed every year by the R&D department 40 active pharmaceutical technology projects every year 1,100 active pharmaceutical licenses formulations We create new employment opportunities of high expertise We expand our exports worldwide (>60 countries) We have three state-of-the-art production units, new independent Research Center and storage space, with a total area of 16,000 sq.m. We are implementing one of the largest investment programs for years 2021-2025 in Greece, amounting to €65 million We rapidly grow our commercial activity in the domestic market and we are expanding our product portfolio. At RAFARM, we are driven by knowledge; that’s why we are constantly developing thus enhancing our expertise in the development and production of ophthalmic and injectable pharmaceutical products. We achieve results that are beyond the obvious due to our team of highly knowledgeable R&D scientists, the cutting-edge technology we apply in production and our holistic approach to regulatory affairs. We act with promptness and agility. We adapt to the needs of the constantly developing pharmaceutical field making use of technology, our customer-oriented approach and primary focus on the individual. Why to partner with us? o Enriched options of complex pharmaceutical products o Flexible business partnerships worldwide o R&D extensive expertise on sterile forms o Focus on time to market o Supplier reliability

Nicox is an international ophthalmic R&D company, based in Valbonne, France, dedicated to developing innovative therapeutics to help maintain vision and improve ocular health.

We focus on addressing significant unmet needs in glaucoma and ocular allergic conjunctivitis, with a leading program, NCX 470, successfully completing Phase 3 clinical development in the U.S. and China. Our portfolio also includes NCX 1728, a candidate under preclinical evaluation for retinal conditions.

Nicox leverages its proprietary nitric oxide donation research platform and strategic collaborations to advance its pipeline. We are proud to offer commercially available products, VYZULTA® for glaucoma and ZERVIATE® for ocular allergic conjunctivitis, with ZERVIATE also approved for use in China.

Bond Chemicals is a Manchester-based global supplier of fine and speciality chemicals, pharmaceutical intermediates, and raw materials for drug development.

We specialize in sourcing alternative commercial sources and custom synthesis, serving a diverse range of clients in the Life Sciences Industry, including those developing drugs across all phases of development.

Bond Chemicals distinguishes itself through its extensive worldwide network of manufacturing partners, offering a comprehensive product range from grammes to multi-tonnes, coupled with a commitment to quality assurance, competitive pricing, and expert technical support.

Founded in 2003, Bond Chemicals operates from its UK headquarters in Warrington, with additional facilities in Dublin (EU) and New Jersey (US), providing seamless supply chain solutions globally.

RotaChrom Technologies is a Hungarian-based industrial chromatography specialist, delivering silica-free, liquid–liquid CPC purification solutions to the pharmaceutical, biotech, botanicals, nutraceuticals, and cosmetics industries. BR Our core offering – Centrifugal Partition Chromatography (CPC) – bridges the gap between bulk extraction and final polishing, ensuring high yield, reproducibility, and gentle handling of sensitive molecules. We specialize in scalable purification, built to grow with your process from R&D to continuous and full industrial production.

RotaChrom’s technology is built on the principles of liquid-liquid separation and CPC, spanning from benchtop through pilot, continuous to industrial-scale CPC systems, complemented by digital method development tools, solvent handling platforms, and automation solutions. We offer expert-led services to de-risk and accelerate your purification path, including chromatography method development, feasibility studies, and technical transfer support. Our team provides the data-driven insights and scalable strategies needed to accelerate your path to market.

Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has advanced to Phase 2 treating patients with multi-drug resistant cancers. Further, Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors, in oncology, auto-immune and inflammatory disorders, having achieved animal in-vivo proof of concept for several new targets. Cellestia was founded in 2014 as a spin-off from EPFL, Lausanne, Switzerland and is headquartered in Basel, Switzerland.

AMPLY Discovery is a drug and nutraceutical discovery company based in Northern Ireland. A spin-out company from Queen's University Belfast, we use machine learning and AI to discover new therapeutic molecules for hard-to-treat diseases. This includes developing new drugs to replace conventional antibiotics and help tackle AMR. Our discovery platform is designed to mine vast biological datasets in silico and validate hundreds of hits in vitro.

We are the first in class pre-clinical translational biophysics company focusing on the discovery of novel therapeutics against intrinsically disordered targets.

We are a precision medicine pioneer in psychiatry based in Munich. Founded in 2010, our privately held biotech company combines the development of machine learning-enabled companion diagnostics with specific therapeutics to personalize the treatment of neuropsychiatric disorders with a focus on depression. Our ultimate goal is to improve the lives of patients by developing highly disruptive solutions for their high unmet medical needs. We strives to reduce not only the immense individual burden, but also the societal impact of these diseases. We develop patented genetic tests and combines those with innovative exclusively in-licensed medications, resulting in precise therapies for depression and other neuropsychiatric disorders.

InFlectis BioScience is a private clinical stage company aiming at targeting and modulating interactions between proteins involved in key human pathophysiological processes. The company is developing small molecule drugs that specifically target the Integrated Stress Response (ISR). Exploiting the ISR’s natural defense offers tremendous potential for the development of a new class of therapies. Led by InFlectis, this area of research is rapidly advancing, resulting in new treatments under development for a variety of disease affecting the central nervous system (CNS), peripheral nervous system (PNS) and inflammation.

Our mission is to create a comprehensive, patient-centric ecosystem that empowers individuals and healthcare professionals alike through a unique digital health platform to bring more quality of life for everyone.

BDD Pharma combines drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and create new value-added products. Rapid parallel clinical testing with BDD SWIFT significantly reduces the time from product concept to clinical success. Recognizing that one size does not fit all we specialise in providing responsive, flexible and innovative solutions to our customers. Our patented delayed release technology OralogiK provides unrivalled control of drug release at the right place and time. Our clinical division provides a full clinical package, including protocol development, study documentation design and regulatory authority submission, through to close out and production of ICH GCP-compliant clinical study report. We specialise in gamma scintigraphy, a powerful and versatile technology used to investigate the in vivo behaviour of your formulation. Coupled with pharmacokinetic data, this technique can be used to provide information on time /site of disintegration, gastric emptying, GI transit and intra/ inter individual differences.

iOmx is a young, dynamic start-up in the field of immuno-oncology located in Martinsried/Munich, Germany. Backed by a powerful technology platform and internationally renowned investors, iOmx is driving forward a cutting-edge portfolio of early-stage novel immune-checkpoint drugs through pre-clinical and clinical development. Imprint: https://iomx.com/imprint

Pharmacy2U is the UK's first and largest online pharmacy. We're a market leader in the pharmacy world, helping over 750,000 patients in England manage their NHS repeat prescriptions from request through to delivery. For over 20 years, we have used cutting-edge technology alongside our UK-based pharmacists, dispensing specialists, and customer care advisers to help improve the lives of patients. Our Leeds and Leicester -based dispensing facilities distribute over 1 million medication items to patients across England every month. KPMG’s Customer Excellence report recently revealed Pharmacy2U is the UK’s number one brand for experience and value, based on a survey of over 10,000 UK consumers. This accolade cements our position as the nation’s go-to online pharmacy and keeps us committed to further broadening our healthcare offering. Our goal is to make simple and convenient healthcare accessible to all. As well as our repeat prescriptions service, patients can also access: - A one-stop online healthcare shop featuring over 4,000 products - Confidential online GP consultations for a range of conditions - Enhanced pharmacy services such as the NHS New Medicine Service We're an ambitious company with big plans and we're looking for talented individuals to join our team and help us to continue excelling in our field. Our CEO Kevin Heath says, “come and join a team that truly lives by our company values of putting the patient at the heart of everything we do”. Want to help shape the future of online healthcare in the UK? Discover our latest vacancies today.

Abionic, an in vitro diagnostics (IVD) company, was founded in 2010 as a spin-off from the Swiss Federal Institute of Technology of Lausanne (EPFL). Abionic is aiming to make a difference in patient care through the cutting-edge nanofluidic technology based ultra-rapid diagnostic platform, helping healthcare professionals to make clinical decisions at the point of care.

AceCann is a Portuguese medical cannabis company that has put together a strong management team with diversified and complementary backgrounds that we trust will make a difference in the global market. The team combines +60 years of healthcare/pharma experience, +11 years operating medical cannabis companies in Canada and Portugal, and +14 years operating with technology/data business. AceCann’s scope of action is: •Organic Medical Cannabis Cultivation & Extraction Facility - building a cost-efficient, scalable and superior quality organic indoor cultivation and extraction facility near Lisbon leveraging on the experience from one or our shareholders •Therapeutics Research & Development - focused on the development of new medical delivery forms for cannabis, joining efforts with local and international universities With a team accustomed to highly volatile environments, AceCann is setting up a flexible structure to learn from a market in constant evolution & change, capable of making fast decisions to scale according to market demands & needs

Alkermes focuses on the development of innovative medicines that seek to address unmet needs of people living with serious mental illness, addiction, and cancer. As a fully-integrated, global biopharmaceutical company, we apply our scientific expertise and proprietary technologies to develop products that are designed to make a meaningful difference in the way patients manage their disease. We are inspired by some of the most pressing public health challenges of our time to help advance innovation with the potential to improve treatment options and outcomes for patients. Beyond our important mission of developing medicines, we believe it is our responsibility to take a holistic approach as we seek to support patients, caregivers, and broader impacted communities. In this context we also work to help support and enhance the systems through which these complex diseases are treated. We are committed to patient engagement, disease education and awareness, and advocacy for important policies that support equitable access to quality treatment. Headquartered in Dublin, Ireland, we have an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. See our Community Guidelines: https://www.alkermes.com/social-community-guidelines

Allero Therapeutics is a Dutch, venture-backed, biopharmaceutical company that develops next generation immunotherapies for immune mediated disorders. Our goal is to develop novel targeted treatments that induce long-lasting antigen-specific tolerance. Our proprietary SOMIT (Specific Oromucosal Immunotherapy) technology combines a tolerance-inducing agent with novel oral patch mediated targeted delivery of specific antigens to the oral mucosa immune privilege.

AMADIX is a leading molecular diagnostics company focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. The mission of the company is extending people's lives, developing disruptive technologies to detect the tumor years in advance, before the symptoms appear.

aptaTargets is a clinical stage biopharmaceutical company focused in developing therapeutic applications based on aptamer technology. Our candidates are neuroprotectants and immunomodulators being developed from preclinical stages up to clinical proof-of-concept.

Aqemia is a pharmatech company using quantum physics and artificial intelligence to transform the drug discovery process. With a unique proprietary technology that preclude the use of experimental data, our pipeline scales the drug discovery process at an unprecedented pace, generating an exhaustive number of new drug candidates. We are hiring! Check our career website: https://jobs.lever.co/aqemia.com Blog Posts on: https://medium.com/aqemia

Ascent Clinical Research Solutions helps pharmaceutical companies transform their ideas and concepts into successful products. We are a highly focused team of professionals who understand how to prepare, manage and conduct clinical trials. Our core activities include but are not limited to Phase I-II-III, post-marketing observation programs for world’s leading biopharmaceutical companies & Bioequivalence studies in numerous patient populations, conducted in our own dedicated hospital-based clinical pharmacology units and under multicenter set-ups in Russia and Georgia.

BC Platforms is a global leader in building data networks for the life sciences industry and provides versatile technology platforms for personalised medicine, accelerating the translation of innovations into clinical practice. We convert complex biological information collected in the healthcare setting into actionable insights. With our innovative technology we are creating a patient centric infinity loop between the life sciences and healthcare sectors. Data we generate, harmonise, and manage, from diverse biobanks and healthcare institutions, is made accessible for pharmaceutical and biotech companies to enhance their core strengths in research and development. In parallel, we enable stratification of patients towards targeted therapies, delivering on the promise of more personalized healthcare. Our high performing genomic data discovery and analytics platform enables flexible data integration, secure analysis, and interpretation of molecular and clinical information. We have developed a Global Data Partner Network, BCRQUEST.com, which allows access to high-quality real-world data. This rapidly growing network has a footprint across many sites, including networks of major hospitals, covering 20 countries in five continents, providing standard of care data for over 23 million patients. Our platforms seamlessly facilitate access to highly enriched data for pharmaceutical research and development. Founded in 1997 from a MIT Whitehead project spinoff, we have a strong scientific heritage underpinned by over 25 years of working in close collaboration with a network of leading researchers, developers, and industry partners. We have global operations with our headquarters in Zurich, Switzerland, R&D in Espoo, Finland, and Singapore, as well as a presence in London and Boston. For more information, please visit www.bcplatforms.com.

Biocellvia is a french company developing Intelligent Image Analysis solutions for pharmaceutical industry (Big Pharma, Biotechs, CRO) and academic communities involved in R&D. We have developed digital image analysis solutions, that enable to evaluate fully-automatically the level of efficacy of your lead molecules thanks to histological slides (in vitro, ex vivo, biopsies) in various pathologies such as: - Gastrointestinal (NASH, Liver fibrosis) - Respiratory (IPF, COPD, PAH) We provide image analysis as a service. Our technology evaluates your molecules with more accuracy, more reliability, more rapidity and less variability than traditional scoring methods. A full study (about 200 images) is performed in only a couple of days. http://biocellvia.com http://linkedin.com/company/biocellvia

New ideas, new innovations, new ways of thinking for the medical device industry. We are a pharmaceutical company specialized in the discovery, clinical development, production and commercialization of innovative products in the field of regenerative medicine. At Bioxis Pharmaceuticals, we contribute to transform science into groundbreaking medical device that meet doctors need to improve the health and well-being of their patients in the field of dermatology and aesthetic medicine.

EpiEndo Pharmaceuticals is an Icelandic clinical stage pharmaceutical company with a unique focus on impairment of epithelial barriers as a common mechanism of many inflammatory conditions such as the airway, gastrointestinal tract and skin. EpiEndo was founded in 2014.

Evotec is a life science company with a unique business model focused on delivering highly effective new therapeutics to the patients. The Company leverages its multimodality platform, the “Data-driven R&D Autobahn to Cures”, for proprietary projects and within a network of partners including Pharma, Biotech, academics, and other healthcare stakeholders. With more than 4,500 highly qualified people at 17 sites, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics.

Anjarium Biosciences AG is a genetic medicines company focused on creating and delivering a new generation of targeted gene therapies to patients. Anjarium’s versatile platform builds on novel therapeutic payloads and delivery technologies, with the aim to unlock the full potential of gene therapy.

BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform™ powers a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York. *Reach out to us* Email: hello@benevolent.ai Careers: Careers@benevolent.ai Twitter: @benevolent_ai Website: benevolent.com

Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical stage biotechnology company that focuses on developing first-in-class breakthrough treatments for CLDN1+ tumors and organ fibrosis. Alentis is pioneering a novel approach to modify and reverse the course of disease progression targeting CLDN1, a previously unexploited target that plays a key role in the pathology of tumors and fibrotic diseases across multiple organs. Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting CLDN1. Alentis’ portfolio of anti-CLDN1 monoclonal antibodies includes a novel class of anti-cancer therapies designed to reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is highly promising for drug development as many cancers use the TME to build barriers that shield against immune system attacks. Alentis’ lead oncology asset, ALE.C04, is the first potential treatment to target CLDN1 in solid tumors. In addition, Alentis’ pipeline includes first-in-class therapies designed to modify and reverse the course of advanced organ fibrosis. ALE.F02, which is currently in Phase 1 clinical trials, is designed to target pathological overexpression of CLDN1 outside of the tight junction to resolve and reverse organ fibrosis and is being investigated for the treatment of fibrotic disease in the kidney, lung, and liver. The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm). Alentis is headquartered in Basel’s pharma-biotech hub in Switzerland with a subsidiary for R&D in Strasbourg, France. For more information, please visit us at www.alentis.ch or write to: info@alentis.ch

C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry. C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company's innovative DNA-based target identification platform (Taxonomy3(R)) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4XD's novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex, that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry. C4X Discovery is advancing its in-house pipeline that is primarily focused on the high value therapeutic areas of inflammation, neurodegeneration and cancer (including immuno-oncology) with a number of new drug candidates identified and further progress made towards the pre-clinical licensing discussions. In selecting new targets and executing new drug discovery programmes, C4X Discovery focuses on high-value disease areas that are the subject of significant licensing activity and will continue to also maximise value from opportunistic areas such as addiction and diabetes. The Company recently signed a licensing agreement with Indivior for a pre-clinical addiction programme worth up to $294m. The Company was founded as a spin-out from the University of Manchester. t has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4XD to reach multiple value inflexion points since IPO. Website: www.c4xdiscovery.com Twitter: @C4XDiscovery

To contact us : contact@calixar.com CALIXAR, is a biotech company specialized in the functional and native isolation of complex membrane therapeutic targets and antigens. We develop and implement chemistry and biochemistry tools to isolate in solution - with the highest purity levels - full-length membrane proteins, while keeping their structural and functional integrity. Our approach represents the opportunity for pharmaceutical companies to start and work with high quality targets or antigens before developing antibodies, formulating vaccines and/or discovering a primary lead through Structure Based Drug Design or High Throughput Screening assays. As membrane proteins represent more than 60% of pharmaceutical drug targets, to keep their native conformation during the extraction from membrane cells and solubilization is crucial. Our technological platform preserves the original structure of membrane proteins such as GPCRs, Ion channels, Transporters, Viral targets, etc.) or others native receptors acting as drug targets or antigens. As a result, this most accurate targeting helps biotechs, academic teams, pharmaceutical industries to develop highly potential drugs, bio drugs and vaccines and consequently saves significant time and money in further clinical stages. By using original chemistry and specific approaches designed on demand, we develop new tools and protocols for the identification, expression, extraction, purification and crystallization of these membrane proteins/antigens from cells or from endogenous materials (virus, bacteria, primary cells, organs, etc.). For SBDD/FBDD approaches, we carry out crystallization tests and structure determination of these native targets starting from their full-length and functional version without any point mutations or deletions. CALIXAR sets up specific R&D programs with its customers using classical and flexible business model: Fee for service, Risk sharing, Exclusivity option and Licensing out.

CV6 Therapeutics is an early stage drug development company focused on the discovery, development and commercialization of novel combination therapies for the treatment of cancer. For further investment questions or opportunities please contact: information@cv6t.com

Cytovation is a clinical stage biotech developing CyPep-1, the first synthetic peptide engineered to selectively target tumor cell membranes based on their altered molecular composition. CyPep-1 lyses the cell membranes, exposes antigenic material from within the cancer cells, and induces a tumor-specific immune response. The described mode of action is effective across cancer types and highly synergistic with checkpoint inhibitors. CyPep-1 has entered clinical development in Q1 2019.

Datacapt provides a global, easy-to-use, flexible, and powerful electronic data capture platform (EDC) for on-site, hybrid, or decentralized Clinical Trials. We allow Sponsors, CROs, and Subjects to work together in a simple way with a huge engagement. Our Platform brings simplicity, efficiency, and quality to the collection of clinical data. Datacapt is making the promise to simplify and accelerate clinical tests with innovative solutions. Simplify the management of your trial with the Datacapt platform. Developed with specialists and experts, our platform is flexible and adapted to your studies. We offer a modular platform with everything in one place to design and manage all your trials (EDC, eCRF, ePRO/eCOA/eDiary, eConsent, eConsult, and Data Analysis…). - Significantly reduced time spent on study setup and management (Simple and flexible eCRF, ePRO, eConsent creation) - Real-time monitoring - Allows reducing manual tasks, data retranscription, and zero time spent on data export - Fast and easy implementation - Secure and 100% Compliant

F-star, an invoX company, is a clinical-stage biopharmaceutical business pioneering bispecific antibodies in immunotherapy so more people with cancer can live longer and improved lives. F-star is committed to working towards a future free from cancer and other serious diseases through the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in treatments. F-star has four second-generation immunooncology therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137. F-star’s proprietary antibody discovery platform is protected by an extensive intellectual property estate, with over 500 granted patents and pending patent applications relating to its platform technology and product pipeline. The Company has attracted multiple partnerships with biopharma targeting significant unmet needs across several areas, including oncology, immunology, and CNS.

Fab’entech is a privately owned biopharmaceutical SME based in Lyon (France) and created in 2009, which develops immunotherapies to address situations of emergency. In an environment where the globalization of trade accelerates the spread of epidemics and where the geopolitical context increases the risk of bioterrorist attacks, nations should be prepared to address various situations of public health & medical emergency. However, there is generally no real therapeutic option to fight acute symptoms arising from these neglected indications. Based on its horse F(ab’)2 platform, a fully-derisked technology in-licensed from Sanofi Pasteur, Fab’entech aims to provide therapeutic solutions in the fields of biodefense, drug intoxication and infectious disease. After having developed Fabenflu®, a product indicated for the treatment of avian influenza (H5N1) in human, Fab’entech is currently focusing on 3 products: a biodefense antidote developed in collaboration with the French army, a treatment for drug intoxication developed in a confidential indication, and an Ebola therapy developed with the support of the European Commission after having been identified by the WHO as the unique therapeutic solution in Europe in 2014.

Gesynta Pharma's drug candidate GS-248 is in clinical phase II development for the treatment of endometriosis – a painful, chronic inflammatory disease that affects about 10 percent of women of reproductive age. Endometriosis often leads to severely reduced quality of life and current drug treatments are inadequate for many patients. Gesynta Pharma aims to exploit the full potential of microsomal prostaglandin E synthase-1 (mPGES-1) as a pharmacological target by developing products in areas of unmet medical need where mPGES-1 inhibition provides clear benefits compared to current therapy. The company's next drug candidate, GS-073, is ready to enter clinical phase I in 2023. Gesynta Pharma bases its R&D on research from the Karolinska Institutet. Major shareholders include Industrifonden, Hadean Ventures, Linc, and a number of successful life science entrepreneurs.

ICONOVO AB is developing proprietary inhalation products for licensing. We have long experience and track record in the development of dry powder inhalers and offer a comprehensive range of devices to our clients. Our selection of device concepts for dry powder inhalation include a reservoir inhaler, a pre-metered inhaler, a capsule based inhaler and a single dose disposable inhaler. We can also provide formulation development, performance testing, documentation and a complete supply-chain.

ImmunOs Therapeutics AG is developing the next generation of immunotherapies that have a role in the innate immune system for cancer and autoimmune diseases. The company is developing therapies that not only have direct anti-tumor effects but also remodel the tumor microenvironment to enhance the efficacy of existing immunotherapies. This portfolio of next generation, novel immunomodulatory proteins target diverse and key immunoregulatory receptors. Our lead program iosH2, now advancing to Phase 1 studies, is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) receptors and thereby activates anti-tumor responses in multiple cancers with monotherapy and in combination with checkpoint inhibitors (CTLA-4, PD-1, PD-L1, CD47) and costimulatory agonists (e.g. 4-1BB).

Livmed's is a software platform that provides home medicine delivery services for fellow citizens and healthcare players.

Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of opioid dependence and chronic pain, rare diseases, oncology and supportive care, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX.

Our vision is to deliver “AI Brains” that closely resemble human brains that perceive, understand and continuously learn. We are achieving our vision through deploying AI capabilities closer to human level intelligence through the use of unlabeled data, unsupervised few-shot learning, knowledge consolidation and sharing. We deliver brain-inspired AI solutions that enable our select customers and partners to maximally exploit the functionality and performance of Brain-Sense™ technology to reduce costs and enhance our customers’ end-product and service capabilities - continuous AI learning of new use cases from unlabelled data using only a few reference examples, and transfers this learnt knowledge across multiple devices. This novel technology enables a set of new possibilities that minimizes the need for big data and allows for faster learning and more intelligent AI that adapts to changing real life conditions.

Minoryx is a registration stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs. The company’s lead program, leriglitazone (MIN-102), a novel, brain penetrant and selective PPAR gamma agonist, is being developed in X-linked Adrenoleukodystrophy (X-ALD) and other orphan CNS diseases. The company is backed by a syndicate of experienced investors, which includes Columbus Venture Partners, CDTI Innvierte, Caixa Capital Risc, Fund+, Ysios Capital, Roche Venture Fund, Kurma Partners, Chiesi Ventures, S.R.I.W, Idinvest Partners / Eurazeo, SFPI-FPIM, HealthEquity, Sambrinvest and Herrecha, and has support from a network of other organizations. Minoryx was founded in 2011, is headquartered in Spain with Belgian facilities and has so far raised more than €120 million

Nuclera is making biology accessible by providing researchers a desktop bioprinter capable to produce genes and proteins in one day. Biological research and drug discovery projects begin with and rely on proteins. However, using traditional methods to obtain proteins of interest can take up to 6 months and often include many trials and failures. What if there was an easier way? At Nuclera, our mission is to better human health by making proteins accessible. We believe that providing rapid access to high-quality, soluble, active proteins at the benchtop will allow researchers to accelerate their protein projects. Fail fast, succeed faster. Our eProtein Discovery™ system automates construct screening for the best soluble expression and purification yields of different proteins in under 24 hours. From there, protein scale-up happens the next day (up to the mg scale) right on the benchtop - delivering reliable protein in-hand in less than 48 hours. Nuclera’s technology integrates cell-free protein synthesis and digital microfluidics on smart cartridges, allowing rapid progress on protein projects through a benchtop, automated, high-throughput protein access system. Founded in 2013 by PhD students at the University of Cambridge, the company now has a presence in Cambridge, UK and Boston, MA employing over 100 employees.

Our mission is to help life sciences companies accelerate drug development for improved patient outcomes, and we do this by championing the power of data. Our main product DISQOVER is an optimized search or knowledge platform which draws on semantic technology and an ontology-based knowledge graph to find links between data across databases (internal data, public data and third party data) faster and more efficiently. The platform has been developed for the pharmaceutical and biotech industries. There are thousands of health research databases, clinical trials, literature reviews, patient studies, etc. available. Before setting up a new study, scientists first need to check what kind of research has already been done – both internally and externally – on, for instance, growth hormone applications for a particular disease. In many companies, even internal information resides in hundreds of different databases, each with their own interface and search logic. As a consequence, just finding this kind of background information is a very time-consuming process. This is where DISQOVER comes in. One of the assets is that we use semantic technology to find logical but often hidden connections between internal and external data, allowing you to easily combine information from a multitude of different sources. As such, pharma and biotech companies can save valuable time and money that they can now invest in developing new medicines or treatments. Customers include: AstraZeneca, AmGen, Medidata, Prinses Máxima Institute, Aelin Therapeutics and more. DISQOVER is used amongst others by scientific researchers, bioinformaticians, and data scientists. Try DISQOVER: our community edition is always up-to-date and accessible via www.ontoforce.com (choose “try now” top right corner)

We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE® (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing our proprietary Exhalation Delivery System™ (EDS®) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). In September 2017, the U.S. Food and Drug Administration (FDA) approved XHANCE for the treatment of nasal polyps in patients 18 years of age or older. XHANCE was made widely available through commercial channels in April 2018. In March and June 2022, we announced positive top line results from our two Phase 3b clinical trials (ReOpen1 and ReOpen2) of XHANCE for a follow-on indication for the treatment of chronic sinusitis. In February 2023, we submitted a prior approval efficacy supplement (sNDA) to support the approval of a new indication for XHANCE for the treatment of chronic rhinosinusitis. If the sNDA is approved, XHANCE has the potential to be the first drug therapy approved by the FDA for the treatment of chronic sinusitis. As of February 20, 2023, we had a total of 141 full-time employees all of whom are in the United States, and no part-time employees. Culture is a critical element in the management of our organization. Our colleagues are focused on driving our business with the Optinose values as the foundation for all our efforts. Our goal is that each colleague feels a deep connection to what they do, loves coming to work and is aligned to our One Mission – to improve lives. Our values of Authenticity, Fearless Conversations, Friendship, Openness, Perseverance and Possibility Thinking guide our actions and decisions.

OSE Immunotherapeutics is an integrated biotech company focused on developing first-in-class assets targeting cancer and inflammatory diseases. A current well-balanced first-in-class clinical pipeline including: • Tedopi® (T-cell specific immunotherapy): Company’s most advanced product; positive results for Ph 3 in NSCLC in secondary resistance after CKI failure. Other sponsored combo Ph 2 trials in solid tumors ongoing. • OSE-279 (anti-PD1) advanced preclinical stage • OSE-127 (humanized mAb antagonist of IL-7R); ongoing Ph 2 in Ulcerative Colitis; ongoing preclinical research in leukemia • VEL-101/FR104 (anti-CD28 mAb) developed in partnership with Veloxis in transplantation; ongoing Ph 1/2 in renal transplant (sponsor Nantes University Hospital); Ph 1 ongoing in the US (sponsor Veloxis). • BI 765063 (anti-SIRPα mAb on CD47/SIRPα pathway) developed in partnership with Boehringer Ingelheim in advanced solid tumors; positive Ph 1 dose escalation results in mono and in combo, in particular with anti-PD-1 antibody ezabenlimab; BI sponsored international Ph 1b clinical trial ongoing in combo with ezabenlimab alone or with other drugs in recurrent/metastatic HNSCC and HCC. OSE Immunotherapeutics expects to generate further significant value from its two proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapeutics: • BiCKI® platform focused on immuno-oncology (IO) is a bispecific fusion protein platform built on the key backbone component of anti-PD1 combined with a new immunotherapy target to increase anti-tumor efficacy. Most advanced BiCKI® candidate is targeting anti-PD1xIL-7. • Myeloid platform focused on optimizing the therapeutic potential of myeloid cells in IO & immuno-inflammation (I&I). OSE-230 (ChemR23 agonist mAb), most advanced candidate generated by the platform, with the potential to resolve chronic inflammation.

UCB – Inspired by patients. Driven by science. At UCB, we put our heart, soul and skills into making a difference for people living with severe diseases. We look to transform patients’ lives by pushing the boundaries of what is possible. With us, our talents makes the most of who they are, unlocking innovation and setting new standards for patients. Everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?” And to find the answers, we connect globally with patients and their families living with the physical and social burdens of severe disease. These connections give us new perspectives, drive our innovation, and offer a hope for a new generation of therapies that will help to transform lives. UCB – The Facts With more than 8700 employees in approximately 40 countries, we are a global biopharmaceutical company headquartered in Brussels, Belgium which invests more than 25% of revenue in cutting-edge scientific research to meet unmet patient needs. A few other reasons that make UCB an amazing place to work: - Promising pipeline that includes several novel molecules; - 2022 Key Financials: €5.5 billion global revenue Specialties: Neurology, Immunology

We are experts in developing novel sub-unit vaccines Our initial focus is on animal health. We aim to capitalize on the first approval of a CrisBio® - based vaccine dossier (expected in 2020) to expand into human health and thereby fully exploit the platform’s potential. CrisBio® also has applications in the Diagnostics sector, where it is already being exploited by a commercial partner. Our current portfolio comprises 6 vaccines across livestock species. Proof of concepts have been generated in > 20 additional vaccine antigens Value through collaborations Our go to market strategy is inherently linked to collaborations. We offer: • Development of tailor-made baculovirus vectors optimized for industrial production. • Proof-of-concept studies to validate the production of recombinant proteins in CrisBio®. • Supply of recombinant proteins produced in CrisBio® through license agreements. • Development of proprietary portfolios. Algenex is led by an internationally experienced management team, that is supported by a well-balanced Strategic Advisory Board that combines industry and investment experience.